Results 101 to 110 of about 6,218 (156)

Medication errors and associated serious outcomes in COVID-19 antivirals: a real-world study based on FDA Adverse Event Reporting System database. [PDF]

Ther Adv Drug Saf
Xiong X, Chen Z, Yan B.
europepmc   +1 more source

From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum. [PDF]

Nat Commun
Khatua K, Atla S, Coleman D, Blankenship LR, Alugubelli YR, Vulupala V, Guo XS, Xia H, Kalveram BK, Walker DH, Hurst BL, Kumar S, Cho CD, Sharma S, Yang K, Rabie D, Nyalata S, Neuman BW, Xie X, Xu S, Liu WR.   +20 more
europepmc   +1 more source

Structure-Based Development of Ultra-Broad-Spectrum 3C-Like Protease Inhibitors. [PDF]

Adv Sci (Weinh)
Su H, Nie T, Chen G, Xiong M, Zhang Y, Wu G, You M, Xie H, He J, Xiong Y, Hu H, Zhao W, Li M, Xiao G, Zhang L, Xu Y.   +15 more
europepmc   +1 more source

Nirmatrelvir methyl <i>tert</i>-butyl ether solvate. [PDF]

Acta Crystallogr E Crystallogr Commun
Smit JP, Purcell DK, Engers DA, Smith PA, Bauser HC, Radocea A.   +5 more
europepmc   +1 more source

Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad. [PDF]

J Am Chem Soc
Atla S, Vulupala V, Alugubelli YR, Blankenship LR, Yang K, Nyalata S, Khatua K, Coleman D, Rabie D, Guo X, Cho CD, Kumar S, Le LHS, Sankaran B, Kalugin JK, Sharma S, Neuman BW, Xu S, Liu WR.   +18 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study. [PDF]

Nat Commun
Guo Z, Wei Y, Lin G, Jia KM, Boyer C, Wang H, Li C, Hung CT, Yam CHK, Chow TY, Zhao S, Li K, Yang A, Mok CKP, Hui DS, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Computational Discovery of MERS-CoV Main Protease Inhibitors Through Screening and Molecular Dynamics Simulations. [PDF]

Proteins
Islam SM, Rahman MS, Singla S, Demissie R, Lee H.   +4 more
europepmc   +1 more source

Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 M^pro inhibitors. [PDF]

Sci Rep
Ibrahim MAA, Khaled DMA, Mahmoud DGM, Abdelrahman AHM, Sidhom PA, Han Y, Shoeib T, Aldahmash B, Rady A.   +8 more
europepmc   +1 more source